EST Time zone (UTC -5)
COMING SOON
Exploring Sarcopenia and Cachexia: Multidisciplinary Perspectives
Welcome to the first day of our Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders. Discover world-renowned experts to discuss the latest research and advancements in the field.
CANCER CACHEXIA
9:30-10:30
Metropolitan ballroom
Session A: Abnormal metabolism in cachexia
Chairs: Tobias Janowitz, USA & Erin Talbert, USA
New insights on the role of purine metabolism in age- and cancer-induced muscle atrophy
Andrea Bonetto, USA
Metabolic crosstalk mechanisms in cancer cachexia
Pauline Morigny, Germany
cAMP/CREB1-derived mitochondrial dysfunctions in cachexia
Andrea Graziani, Italy
Causal mechanisms in the mouse model of cancer cachexia – Lewis Lung – Carcinoma
Xavier Clemente-Casares, Canada
Chairs & Speakers
Stefan Anker, Germany
Vickie Baracos, Germany
GENERAL SARCOPENIA
10:45-11:45
Metropolitan ballroom
Session B: New findings on muscle wasting
Chairs: Peggy Cawthon, USA & Simon Wing, Canada
Identifying Mytho as a new regulator of muscle autophagy
Sabah Hussain, Canada
EDA2R-NIK signaling promotes muscle atrophy linked to cancer cachexia
Serkan Kir, Turkey
Regulation of muscle sarcomere maintenance and bioenergetics by an unsuspected E3 ligase: a new myopathy gene
Jorge Ruas, USA
GLP-2 treatment improves muscle recovery following starvation in rats: a clinical opportunity to reverse muscle wasting?
Didier Attaix, France
BREAK
12:00-12:50
Lunch Break
Industry Session
12:00-12:45
Metropolitan ballroom
Keynote Industry Lecture
MRI-based quantification of muscle mass and myosteatosis as biomarkers for clinical trials and sarcopenia assessment
Olof Dahlqvist Leinhard, Sweden
Key Topics Addressed
– Standardization and validation of MRI-based muscle mass and myosteaotosis measurement for use in multi-site clinical trials
– Body size as a major confounder for sarcopenia assessment
– How combined assessment of muscle mass and myosteatosis improves link to outcomes & function
– MRI based muscle assessment as end-point in clinical trials, experiences from recent GLP-1 and neuromuscular dystrophy trials
Supported by AMRA Medical
Opening Session
13:00-14:00
Metropolitan ballroom
Session C: Opening Session
Chairs: Stefan Anker, Germany & Stephan von Haehling, Germany
Welcome
Stefan Anker, Germany
“Prometheus” basic science key note lecture:
Evolution of Cachexia – Adaptive to Maladaptive
Teresa Zimmers, USA
“Hippocrates” clinical science key note lecture:
Integrate the power of preventive nutrition, (p)rehabilitation and positive psychology into cancer cachexia management
Florian Strasser, Switzerland
JCSM & SCWD lecture
Stephan von Haehling, Germany
Stefan Anker, Germany
Break
14:00-14:10
METROPOLITAN BALLROOM
MECHANISMS, DIAGNOSTICS
Session D
14:10-15:15
Advances on the roles of cancer-released extracellular vesicles in cachexia
Chairs: James Carson, USA & Denis Guttridge, USA
Cancer-cell-secreted extracellular vesicles dysregulate proteolysis and mitochondrial function in skeletal muscle
Shizhen (Emily) Wang, USA
The art of war: blocking the secretion of extracellular vesicles from cachexia-inducing tumors
Sai V. Chitti, Australia
The role of extracellular vesicles in adipose tissue
Wei Yan, China
Chemotherapy drugs 5-FU and cisplatin promote cachexia by stimulating extracellular vesicle release from cancer
Yi-Ping Li, USA
DUPONT BALLROOM
CANCER CACHEXIA
Session E
14:10-15:15
Understanding dysregulated metabolic homeostasis in cancer cachexia
Chairs: Elke Dworatzek, Germany & Steven Heymsfield, USA
Tumor-induced physiological changes in the host in cachexia
Eileen White, USA
Identifying metabolic alterations in cancer cachexia: quantitative fluxomics
Sheng Tony Hui, USA
Imaging metabolic adaptions in cancer cachexia using positron emission tomography (PET)
David Lewis, UK
Improving insulin sensitivity to treat cancer cachexia in humans
Justin Brown, USA
Coffee Break
15:15-16:15
WEST END & THOMAS ROOMS
POSTER SESSION
Poster Session 1
15:20-16:10
Poster session 1.1 Cachexia – mechanisms, basic
Posters 1-01 to 1-09 and 1-12
Chairs: Denis Guttridge, Sarah Lockie
Poster session 1.2 Cancer cachexia I
Posters 3-01 to 3-12
Chairs: Andrea Bonetto, Tobias Janowitz
Poster session 1.3 Diagnosis of cachexia
Posters 4-01 to 4-11
Chairs: Yi-Ping Li, Ishan Roy
Poster session 1.4 Muscle wasting & sarcopenia I
Posters 6-01 to 6-08
Chairs: Peggy Cawthon, Bill Evans
Poster session 1.5 Nutrition & appetite
Posters 7-01 to 7-07
Chairs: Adrian Slee, Paula Ravasco
Poster session 1.6 Physical activity & training
Posters 8-01 to 8-06
Chairs: Volker Adams, Julian Alcazar
METROPOLITAN BALLROOM
ABSTRACT SESSION
Rapid Fire Abstracts Session 1
15:20-16:10
Chairs: Mauricio Berriel Diaz, Germany & Andrea Graziani, Italy
Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia (1-10)
Victoria Spadafora, USA
Differential impact of chemotherapy and cachexia in a preclinical colorectal cancer model: a comparative analysis of 5-FU, paclitaxel, and cisplatin by biological sex (1-11)
Regina Cabrera , USA
Pilot study of urine titin N-fragment in dogs with naturally-occurring cardiac cachexia (1-22)
Lisa Freeman, USA
Novel genetic variants in DRAIC and RFX3 confer risk for weight loss in people with chronic obstructive pulmonary disease (2-01)
Joe W. Chiles, UK
Mutual de-differentiation of adipocytes and tumor cells in the macroenvironment of pancreatic cancer cachexia (2-09)
Sephora Jean, USA
ASCA101 as innovative multi-target therapeutic drug for cancer cachexia (10-07)
Minhyuk Yun, South Korea
Dual targeting of Y5 and ghrelin receptors: a new strategy for treating cancer cachexia (10-10)
Jenna Hunt, Denmark
Pharmacological inhibition of USP-19 attenuates cancer cachexia-induced muscle atrophy (10-12)
Vignesh Karthikaisamy, Germany
Bimagrumab prevents semaglutide-induced muscle mass loss in diet-induced obese mice (10-13)
Morten Lundh, Denmark
Loss of hindlimb muscle mass does not explain the loss of lean mass in semaglutide-treated mice (10-14)
Takuya Karasawa, USA
16:15-17:30
DUPONT BALLROOM
NUTRITION
Session F
Nutrition and translational cachexia research
Chairs: Steven Olde Damink, The Netherlands & Stephan von Haehling, Germany
Nutritional treatment options in cancer care
Paula Ravasco, Portugal
Microbiota and nutrition in oncology: new player?
Carolina Trabulo, Portugal
Balanced nutrition to prevent proetin-energy wasting and preseve renal function in chronic kidney diesease
Kamyar Kalantar-Zadeh, USA
Uncoupling chronic cardiac wasting-associated cardiomyopathy from tumor and skeletal muscle wasting in cancer cachexia
Joseph Metzger, USA
METROPOLITAN BALLROOM
GENERAL SARCOPENIA
Session G
Body composition changes induced by GLP1-RA in obesity therapy
Chairs: Andrew Coats, Australia & Jennifer Linge, Sweden
The GLP1-RA evidence base for clinical benefits in obesity
Javed Butler, USA
How do GLP1-RA cause weight loss?
Henning Langer, Germany
The use of muscle selective anabolics to make GLP-1 RA weight loss drugs more effective and precise
Mitchell Steiner, USA
Body composition changes when giving GLP1-RA
Stefan Anker, Germany
Anabolic co-treatment in obesity therapy: rationale and early data
David Glass, USA
Panel discussion
METROPOLITAN BALLROOM
17:45-18:30 SYMPOSIUM
Innovations in cancer cachexia
Moderators: Stefan Anker, Germany & Andrew Coats, Australia
Cancer cachexia: new pharmacological approaches
Richard Skipworth, UK
Are patients reported outcomes meaningful endpoints in cachexia trials?
Stacie Hudgens, USA
Innovation in cancer cachexia: S-pindolol a new therapeutic approach
Andrew Coats, Australia
Discussion
Symposium supported by Actimed Therapeutics
Register Now!
Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.
Day 2: Saturday, 7 December 2024
Comprehensive Exploration of Cancer Cachexia and Aging-Related Sarcopenia
Discover the second day of our programme, dedicated to exploring the complexities of cancer cachexia and aging-related sarcopenia. With a stellar lineup of international experts presenting their latest research and engaging in insightful panel discussions
CAREER CAFÉ
08:00-08:50
Ken Fearon Career Café
(attendance upon application and confirmation)
09:00-10:15
METROPOLITAN BALLROOM
GENERAL CACHEXIA
Session H
Multimodal interventions for cachexia
Chairs: Kam Kalantar Zadeh, USA & Mitja Lainscak, Slovenia
Multimodal interventions in cancer and heart failure cachexia
Masaaki Konishi, Japan
Multi-Modal Integrated Exercise, Anti-inflammatory and Dietary counselling (MMIEAD) for kidney cachexia: Protocol for a cRCT
Joanne Reid, UK
Update on nutrition and exercise interventions in renal cachexia
Adrian Slee, UK
Multi-modal therapy in cancer cachexia: what do the ENERGY and other trials tell us
Richard Skipworth, UK
DUPONT BALLROOM
CANCER CACHEXIA
Session I
Treatment-induced muscle deficits in cachexia
Chairs: Andrea Bonetto, USA & Paola Costelli, Italy
Mechanisms of radiation-induced muscle fibrosis
Michael De Lisio, Canada
Immune cell signature in chemotherapy-induced cachexia
Brandon VanderVeen, USA
Sex dependent effects in chemotherapy-induced cachexia
Nicholas Greene, USA
Musculoskeletal consequences of pediatric radiotherapy
Joe Chakkalakal, USA
Coffee Break
10:15-11:15
WEST END & THOMAS ROOMS
POSTER SESSION
Poster Session 2
10:20-11:10
Poster session 2.1 Cachexia – mechanisms, animal models II
Posters 1-10 to 1-11 and 1-13 to 1-22
Chairs: Denis Guttridge, Sarah Lockie
Poster session 2.2 Cancer cachexia II
Posters 3-34 to 3-42
Chairs: Joanne Reid, Florian Strasser
Poster session 2.3 Diagnosis of sarcopenia I
Posters 5-05 to 5-12
Chairs: Richard Skipworth, Faisal Beg
Poster session 2.4 Muscle wasting & sarcopenia – mechanisms II
Posters 6-16 to 6-24
Chairs: Peggy Cawthon, Bill Evans
Poster session 2.5 Therapeutic development (clinical)
Posters 9-01 to 9-11
Chairs: Nicholas Brisson, Tobias Winkler
METROPOLITAN BALLROOM
ABSTRACT SESSION
Rapid Fire Abstracts Session 2
10:20-11:10
Chairs: Elke Dworatzek, Germany & Wei Yan, China
Improved immune response and energy metabolism in the C26 tumor-bearing mice exposed to IL4 (3-03)
Giacomo Rubini, Italy
The dynamic role of cardiac-infiltrating neutrophils in pancreatic cancer-induced cardiac dysfunction (3-05)
Aaron Grossberg, USA
Impact of the emerging cancer cachexia-biomarker TIMP-1 on the liver (3-18)
Vanessa Brunner, Germany
Cancer Cachexia epidemiological landscape: lifetime prevalence and severity of cachexia in a population-based longitudinal study (3-21)
Bhumi Bhatt, Canada
Adiposity specific micrornas in cancer patients: analysis of plasma levels according to fat distribution assessed by CT-scan (3-25)
Federica Tambaro, Italy
Increased nivolumab clearance correlates with elevated GDF15 serum levels in patients with metastatic non-small cell lung cancer (3-29)
Wouter van de Worp, The Netherlands
Identifying pretreatment blood metabolic markers associated with weight loss in head and neck cancer patients (3-33)
Ronald Eldridge, USA
Practical cancer nutrition, from guidelines to clinical practice: the mypath® project (7-01)
Barry Laird, UK
Differences on the prevalence of anorexia and clinical manifestations in patients with solid and hematological tumors who attend a tertiary care hospital from 2023 to 2024 (7-03)
María del Pilar Milke García, Mexico
Intermittent hypoxic-hyperoxic training during inpatient rehabilitation improves exercise capacity and functional outcome in patients with long COVID: results of a controlled clinical pilot trial (8-06)
Wolfram Doehner, Germany
11:15-12:30
METROPOLITAN BALLROOM
CANCER CACHEXIA
Session J
Cancer cachexia – hot topics
Chairs: Egidio Del Fabbro, USA & Mitja Lainscak, Slovenia
Is Cancer-Reated Fatigue (CRF) in advanced cancer equal to cachexia?
Florian Strasser, Switzerland
Potential relevance of blood mitochondrial gene expression in sarcopenia and fatigue
Amber Kleckner, USA
GDF-15 neutralizing antibody visugromab overcomes cancer cachexia
José Medina-Echeverz, Germany
DUPONT BALLROOM
MECHANISMS, DIAGNOSTICS
Session K
Novel approaches to the diagnosis of sarcopenia: translating research into practice
Chairs: Hidenori Arai, Japan & Bill Evans, USA
Sit-to-stand muscle power at the core of sarcopenia assessment
Julian Alcazar, Spain
D3Cr muscle mass as a clinically feasible assessment of muscle quantity
Peggy Cawthon, USA
Artificial intelligence to diagnose sarcopenia in CT and MRI images
Gustavo Duque, Canada
New biomarkers for sarcopenia
Marie-Theres Huemer, Germany
Break
12:30-13:45
Lunch Break
symposium
12:45-13:30
METROPOLITAN BALLROOM
GDF-15 inhibition: evolving insights
Chairs: Jeffrey Crawford, USA & Stefan Anker, Germany
Introductory remarks
Jeffrey Crawford, USA & Stefan Anker, Germany
Biological basis for GDF-15 inhibition
Danna Breen, USA
Potential therapeutic approaches to inhibiting GDF-15 in cancer cachexia and heart failure
John Groarke, USA
Q&A
Symposium supported by Pfizer
13:45-15:00
METROPOLITAN BALLROOM
MECHANISMS, DIAGNOSTICS
Session L
Biomarkers in muscle wasting: The intersect between cachexia, sarcopenia and frailty
Chairs: John Batsis, USA & Francesco Landi, Italy
Biomarkers of sarcopenia and cachexia in prostate cancer patients. The ADT Study
Jose Garcia, USA
Biomarkers of cachexia in cardiovascular disease
Stephan von Haehling, Germany
Biomarkers of frailty
Luigi Ferrucci, USA
Functional biomarkers of cancer cachexia
Ishan Roy, USA
DUPONT BALLROOM
GENERAL SARCOPENIA
Session M
Muscular disorders in critically and chronically ill patients
Chairs: Joerg Schefold, Switzerland & Tobias Winkler, Germany
Experimental studies on Critical Illness Myopathy: Underlying mechanisms and intervention studies
Lars Larsson, Sweden
Critical illness myopathy and critical illness polyneuropathy: pathophysiology
Coen Ottenheijm, The Netherlands
Critical illness associated (neuro-) muscular disorders
Joerg Schefold, Switzerland
Fasting associated muscle and fat tissue loss – the data, the mechanisms
Faiza Kalam, USA
Coffee Break
15:00-16:00
WEST END & THOMAS ROOMS
POSTER SESSION
Poster Session 3
15:05-15:55
Poster session 3.1 Cachexia – mechanisms, basic
Posters 2-01 to 2-11
Chairs: Nicholas Greene, Andrew Judge
Poster session 3.2 Cancer cachexia III
Posters 3-13 to 3-23
Chairs: Joanne Reid, Florian Strasser
Poster session 3.3 Diagnosis of sarcopenia II
Posters 5-01 to 5-04 and 5-13 to 5-15
Chairs: Faisal Beg, Richard Skipworth
Poster session 3.4 Muscle wasting & sarcopenia III
Posters 6-25 to 6-32
Chairs: Wolfram Doehner, Sabbah Hussain
Poster session 3.5 Therapeutic development (pre-clinical) I
Posters 10-01 to 10-07
Chairs: Paola Costelli, Jeffrey Crawford
METROPOLITAN BALLROOM
ABSTRACT SESSION
Rapid Fire Abstracts Session 3
15:05-15:55
Chairs: Gustavo Duque, Canada & Reshma Merchant, Singapore
Associations of low lean mass by EWGSOP2, FNIH and EASO/ESPEN and MRI muscle composition with all-cause mortality across BMI classes (5-05)
Jennifer Linge, Sweden
Comparing predictive ability of sarcopenia definitions using muscle ultrasound for clinical outcomes among older inpatients (5-10)
Nicola Merz, Switzerland
Assessing the validity of serological biomarkers in estimating muscle mass: a retrospective cross-sectional NHANES analysis (5-12)
Christian Arias, USA
AMPK in skeletal muscle as a therapeutic target for sarcopenic obesity (6-07)
Haiming Kerr, USA
The role of hepatokines in MASLD associated muscle wasting (6-13)
Amy Rose Fumo, Germany
MyoMed-205 counteracts titin hyper-phosphorylation, muscle dysfunction and atrophy in an animal model of HFpEF (6-14)
Beatrice Vahle, Germany
Angiotensin type 2 receptor deficiency exacerbates physical decline and cardiac muscle wasting in aged mice (6-15)
Michael Abadir, USA
Radiation reduces fibro/adipogenic progenitor-derived follistatin-like 1 to impair myoblast differentiation (6-16)
Cooper Brabrook, Canada
Impact of Ilk1 and Fermt2 AAV-mediated knockdown on sepsis-induced muscle weakness (6-17)
Alexander Pacolet, Belgium
Effect of caffeine consumption in patients undergoing immunotherapy for melanoma and lung cancer (7-06)
Paula Ravasco, Portugal
16:00-17:15
METROPOLITAN BALLROOM
NUTRITION
Session N
Metabolic and nutritional changes in advanced cancer
Chairs: Tateaki Naito, Japan & Wolfram Doehner, Germany
Body adipose tissue changes in women with advanced breast cancer
Alessio Molfino, Italy
Nutritional consideration in patients with advanced cancer
Egidio Del Fabbro, USA
Pancreatic cancer cachexia: is it nutrition-sensitive?
Maurizio Muscaritoli, Italy
Selected abstract talk:
Early signatures of cachexia in pancreatic cancer: the importance of fat tissue
Adam Kuchnia, USA
DUPONT BALLROOM
MUSCLE WASTING
Session O
Muscle wasting in critical illness and injury
Chairs: Teresa Zimmers, USA & Joerg Schefold, Switzerland
The physiological rationale for cachexia: recovery from organ injury
Tewfik Hamidi, USA
Burn-induced cachexia
Jeevendra Martyn, USA
Persistent Inflammatory/Immunosuppressive Catabolic Syndrome (PICS) after sepsis
Philip Efron, USA
Sepsis-induced muscle weakness and dysfunction
Hiroshi Saito, USA
Break
17:15-17:30
Break
17:30-18:45
METROPOLITAN BALLROOM
GENERAL CACHEXIA
Session P
Artificial Intelligence for cachexia and sarcopenia
Chairs: Luigi Ferrucci, USA & Richard Skipworth, UK
Using AI to identify early cachexia; results from national database
Michael Yule, UK
Artificial intelligence for body composition and sarcopenia evaluation on computed tomography
Faisal Beg, Canada
RNAome Guided Classification of Human Skeletal Muscle Subtypes in Cancer Cachexia (AI-non-negative matrix factorization method)
Vickie Baracos, Canada
Selected abstract talk:
Automatized workflows for assessing the dynamics of muscle wasting
Wouter van de Worp, The Netherlands
DUPONT BALLROOM
GENERAL SARCOPENIA
Session Q
The association of sarcopenia on organ and system dysfunction
Chairs: Wolfram Doehner, Germany & Reshma Merchant, Singapore
Cardiometabolic effect
Andrew Coats, Australia
Osteosarcopenia
Gustavo Duque, Canada
Effect on cognition
Miguel Borda, Norway
Fat and muscle interactions in the context of obesity
John Batsis, USA
Register Now!
Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.
Day 3: Sunday 8 December 2024
Exploring the Intricacies of Muscle Wasting and Microbiome in Cancer Cachexia
Day three of our programme plunges us into the intricacies of muscle wasting and the microbiome’s influence in cancer cachexia. We are pleased to present a distinguished gathering of international experts, eager to share their groundbreaking research and partake in dynamic discussions.
Award Session
8:00-8:50
METROPOLITAN BALLROOM
Young Investigators Award Session
Chairs/Judges: Zaver Bhujwalla, USA, Samuel Breit, Australia, Lars Larsson, Sweden, Florian Strasser, Switzerland & Eileen White, USA
Pancreatic cancer induces population-specific, heterogeneous activation of cachexia genes and reverts differentiation in skeletal muscle myocytes (1-09)
Brittany Counts, USA
The LEAP2 response to cancer-related anorexia-cachexia syndrome (2-07)
Salil Varshney, USA
KPC pancreatic cancer disrupts the skeletal muscle circadian transcriptome in a FoxP1-dependent manner (2-08)
Jeremy Ducharme, USA
An exploration of the GLIM inflammation criteria to predict survival in patients with advanced cancer (4-02)
Chattarin Pumtako, UK
Ubiquitous and unseen: cancer cachexia at the end of life (4-09)
Michael Yule, UK
Multi-kinase inhibitor Sorafenib triggers cachexia by disrupting the activity of distinct chromatin regulators (2-04)
Bushra Khan, Germany
9:00-10:15
METROPOLITAN BALLROOM
GENERAL CACHEXIA
Session S
Neural control of cachexia – covering appetite control, neuroinflammation to metabolism
Chairs: Aaron Grossberg, USA & Puneeth Iyengar, USA
Neural control of anorexia
Tobias Janowitz, USA
Appetite control and metabolic changes in cancer cachexia
Marcus Goncalves, USA
Alterations in brain metabolites in pancreatic cancer cachexia
Zaver Bhujwalla, USA
The role of the leptin pathway in amplifying the anorexic effects of GDF15
Samuel Breit, Australia
DUPONT BALLROOM
GENERAL SARCOPENIA
Session T
Advanced biologic and motion therapies for musculoskeletal diseases
Chairs: Vickie Baracos, Canada & Hidetaka Wakabayashi, Japan
HIPGEN – Lessons learned from a Phase III study on allogeneic cell therapy for muscle regeneration in
hip fracture patients
Tazio Maleitzke, Denmark
Regulatory T-cell targeting biomaterials for skeletal muscle regeneration
Brian Kwee, USA
PROTO – Digital training therapy for correction of movement after ligament surgery in knee patients
Nicholas Brisson, Canada
The Advanced Therapies in Orthopaedics Alliance (ATiO) – an endeavour to create the medicine of the future for musculoskeletal diseases
Tobias Winkler, Germany
Coffee Break
10:15-11:15
POSTER SESSION
10:20-11:10
west end & thomas rooms
Poster Session 4
Poster session 4.1 Cancer cachexia IV
Posters 3-24 to 3-33
Chairs: Andrea Bonetto, Tobias Janowitz
Poster session 4.2 Muscle wasting & sarcopenia IV
Posters 6-09 to 6-15
Chairs: Wolfram Doehner, Sabah Hussain
Poster session 4.3 Therapeutic development (pre-clinical) II
Posters 10-08 to 10-14
Chairs: Paola Costelli, Jeffrey Crawford
LATE BREAKING
11:15-12:30
METROPOLITAN BALLROOM
Session U: Late Breaking Trials/Science
Chairs: Stefan Anker, Germany, Andrew Coats , Australia, Jose Garcia, USA & John Groarke, USA
Cachexia in chronic illness – results of a country-wide registry
Mitja Lainscak, Slovenia
MENAC – a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with incurable lung or pancreatic cancer undergoing systemic anti-cancer therapy (9-08)
Barry Laird, UK
A synbiotic improves muscle strength, mass and performance in older Australians: preliminary results from a randomized, controlled trial (9-02)
David Barry, Australia
BIO101: a drug candidate to reduce GLP1-RA-induced muscle mass or function loss in patients with obesity (9-11)
Rob Van Maanen, France
Cancer Appetite Recovery Study (CAReS): Phase 1 dose-ascending, multicenter trial of ART27.13 in patients with cancer anorexia and weight loss
Barry Laird, UK
Optimal responders to anamorelin: insights from ROMANA trials (3-28)
Richard Skipworth, UK
Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia (9-10)
Jeffrey Crawford, USA
Break
12:30-13:30
Lunch Break
Symposium
12:45-13:20
METROPOLITAN BALLROOM
Diagnosing and reporting cachexia: Where are we?
Chairs: Stefan Anker, Germany, & Andrew Coats, Australia
How to diagnose cachexia in 2025
Stephan von Haehling, Germany
Cachexia coding: facts, numbers, and challenges
Mitja Lainscak, Slovenia
How to increase awareness about body wasting and cachexia
Wolfram Doehner, Germany
Symposium supported by Splošna bolnišnica Murska Sobota
13:30-14:45
METROPOLITAN BALLROOM
GENERAL CACHEXIA
Session V
Metabolic alterations & damage of certain organs in cachexia
Chairs: Andrea Bonetto, USA & Andrew Judge, USA
What about the diaphragm in cachexia
Volker Adams, Germany
IL-6 induces early cachexia via hepatic STAT-3
Aaron Grossberg, USA
Leukemia inhibitory factor impact on hepatic lipid metabolism
Wenwei Hu, USA
Transcriptional reprogramming of the liver in cancer cachexia
Mauricio Berriel Diaz, Germany
DUPONT BALLROOM
CANCER CACHEXIA
Session W
Ghrelin in cancer cachexia: Exploring Innovative Horizons
Chairs: Samuel Breit, USA & Barry Laird, UK
Interrogating the Ghrelin-AgRP system in the KPC mouse model
Sarah Lockie, Australia
Macimorelin results from a pilot trial and future directions
Jose Garcia, USA
Anamorelin in Japan
Hidetaka Wakabayashi, Japan
Biology of PEP-64 – a long-acting stabilized ghrelin analogue
Jenna Hunt, Denmark
HIGHLIGHTS
14:45-15:45
METROPOLITAN BALLROOM
Highlights Session
Chairs: Vickie Baracos, Canada & Jeffrey Crawford, USA
Basic Science
Erin Talbert, USA
Nutrition
Florian Strasser, Switzerland
Sarcopenia
Hidenori Arai, Japan
Cancer Cachexia
Aminah Jatoi, USA
Poster Award
Young Investigator Award
Farewell
Supporting SCWD's Mission to Advance Medical Research
Our Valued Sponsors 2023
